A U.S. and Canada study shows that ASA 300 mg daily does not improve risk of breast cancer recurrence or survival in individuals with high-risk nonmetastatic breast cancer.
While increasing age remains a risk factor, researchers found each age group examined saw more diagnoses when comparing data from 1984 to 1988 and 2015 to 2019.